NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.
about
Role of central dopamine in pain and analgesiaPAOPA, a potent analogue of Pro-Leu-glycinamide and allosteric modulator of the dopamine D2 receptor, prevents NMDA receptor antagonist (MK-801)-induced deficits in social interaction in the rat: implications for the treatment of negative symptoms iA brief history of the development of antidepressant drugs: from monoamines to glutamateRestoration of Sp4 in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in Sp4 Hypomorphic Mice.The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaDrug models of schizophreniaJumping to conclusions in schizophreniaAn animal model of emotional blunting in schizophrenia.Chronic ketamine administration modulates midbrain dopamine system in miceDopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimeticsKetamine self-administration in the rat: evidence for a critical role of setting.The effects of ketamine and risperidone on eye movement control in healthy volunteers.Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia.Effects of bisphenol-A and other endocrine disruptors compared with abnormalities of schizophrenia: an endocrine-disruption theory of schizophrenia.Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotionGlutamatergic modulation of auditory information processing in the human brain.Behavioral effects of prenatal ketamine exposure in rhesus macaques are dependent on MAOA genotype.A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in miceOxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonismNMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness.Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.Reviewing the ketamine model for schizophrenia.Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studiesInvestigational drugs in recent clinical trials for treatment-resistant depression.Selective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis.Novel pharmacotherapy for fibromyalgia.Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.Drug Abuse and Psychosis: New Insights into Drug-induced PsychosisRecent insights into the mode of action of memantine and ketamineAnti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.Schizophrenia: a systemic disorderComplex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophreniaImpact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons.Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant actionPerformance on a probabilistic inference task in healthy subjects receiving ketamine compared with patients with schizophreniaKetamine decreases inflammatory and immune pathways after transient hypoxia in late gestation fetal cerebral cortexImaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?Ketamine regulates the presynaptic release machinery in the hippocampus.
P2860
Q22241489-12340879-270C-4D5C-A2AC-712538CF4F3CQ24621061-00B26F9D-5AB5-4D2F-AFE1-1EF169F0311BQ27028050-275C75EB-F16C-4E31-BC4B-D52210745F45Q27300750-37480445-6082-4A82-8A1F-8B5266DF9B17Q28081110-D0DA3BE1-FCC0-40B3-9D8E-C23DD25C4473Q28084198-8907DEB6-0C9D-4076-82E4-E60FD8AFD65AQ28087488-2F6D582F-4197-4DD0-8709-08E24AE661F5Q28471824-A4133703-EEE5-4110-8133-8A068F741525Q28482530-16354074-A76B-4E61-A8CC-20D98393B485Q28575182-0BFB8D16-6F2F-4979-9B68-D0F436716EC0Q30396136-C9C8B1A9-9C5A-4DA2-8AC4-E5D038520288Q30437913-B5F7ED4E-3D3D-4C6B-B021-F423F5EBB4ACQ30452766-7E90D9D8-29BA-41EF-9013-092BC2AEF441Q30490910-03419EBA-1F5B-4409-8BC0-4D3CF8BDB756Q30493214-7F63443C-2C0E-4B77-AB4B-834B8FCFDBA6Q30506046-B1432DA5-5381-4C66-8731-9EDE73261039Q30527669-530FE424-3298-4E48-93A5-FE9104B8713CQ30651885-0F098D63-1E82-453A-B86D-43F1A6461B94Q30659389-7EC5D01E-14E1-44F4-925B-C803F17F58D8Q33496712-7385DB8A-8760-4951-94D6-CDB2BC087211Q33936354-6DF8EC3F-D380-4CE6-B361-8FF1E9581456Q34046060-FD5DCEC5-A3D0-47E6-84AF-8170DC5F7D1AQ34127075-995E3335-4F28-479A-BD33-8FBDE2DE873AQ34549390-2C9FB533-18A0-459F-A27A-CF99F893DE21Q34579973-0C255707-DD78-4104-9799-F877662DB37DQ34628135-008BB199-2780-421D-9842-E26F292A1F8AQ34661281-B2246101-BBA4-431D-AD06-F3CD115508CBQ34680922-94D73091-95F0-4766-A313-A2B605462ED4Q35054539-FD5185DA-12B9-4873-874F-DD9989CF29EDQ35150163-33BDA9A0-33B5-4EB5-AD69-12ADDE846840Q35323907-22B52F77-93FF-4BD2-AE67-053D7ABE9034Q35613651-B2E8121E-AE73-4594-9AB3-1A095867D004Q35748576-25C1D002-3C67-441D-9DE6-46B1AD1B2A8AQ36020138-411018A0-DC89-4FFE-960C-45A1A6B9A026Q36538176-48AB4D0E-FF08-4822-AC6E-001C91459625Q36748319-9180881F-CA77-4885-9EC0-2D8831BA6CEDQ36860038-1FE8B87F-8A52-4FA4-9703-698546C0C058Q36860042-8125E485-B0EE-48EB-9E5D-A024851E96E6Q36860053-A91FCFF8-DADC-45CE-9758-06C22DB249B5Q36919594-C8F049E6-64D2-4539-B40E-9168FB80A6A1
P2860
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D
@nl
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@ast
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@en
type
label
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D
@nl
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@ast
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@en
prefLabel
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D
@nl
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@ast
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@en
P2860
P356
P1433
P1476
NMDA receptor antagonists keta ...... s for models of schizophrenia.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.MP.4001093
P407
P50
P577
2002-01-01T00:00:00Z